A supplemental Biologics License Application (sBLA) was submitted to the U.S. Food and Drug Administration (FDA) and a Type II Variation Application was submitted to the European Medicines Agency (EMA) by Janssen, seeking approval of CARVYKTI ® ( ciltacabtagene autoleucel; cilta-cel) for the

New and updated data from the CARTITUDE Clinical Development Program and LEGEND-2 study evaluating ciltacabtagene autoleucel (cilta-cel) will be presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting and the European Hematology Association’s (EHA) 2023 Hybrid Congress

CARTITUDE-4, a Phase 3 study of CARVYKTI ® (ciltacabtagene autoleucel) meets primary endpoint at the study’s first pre-specified interim analysis FDA clearance of IND application for LB2102 in Extensive Stage Small Cell Lung Cancer (SCLC) CARVYKTI ® (ciltacabtagene autoleucel) receives approval